PMID- 12797451
OWN - NLM
STAT- MEDLINE
DCOM- 20030630
LR  - 20190901
IS  - 0070-217X (Print)
IS  - 0070-217X (Linking)
VI  - 276
DP  - 2003
TI  - Viral vectors for dendritic cell-based immunotherapy.
PG  - 241-59
AB  - Dendritic cells (DCs) constitute a specialised system of antigen-presenting cells 
      with a high capacity to induce and to modulate the immune response against 
      microbial, tumour and self-antigens. New techniques to generate large amounts of 
      DCs together with the molecular identification of human tumour-associated 
      antigens (TAA) have opened new ways for antigen-specific cancer immunotherapies. 
      DCs loaded either with TAA-derived MHC class I-specific synthetic peptides or 
      with whole tumour cell preparations have been used in numerous clinical trials 
      evaluating the efficacy of DCs in patients with cancer. However, the 
      disadvantages of DCs pulsed with synthetic peptides from TAA include the 
      uncertainty regarding the longevity of antigen presentation, the restriction by 
      the patient's haplotype and the relatively low number of known MHC class I and in 
      particular of MHC class II helper cell-related epitopes. Whole tumour cell 
      preparations are difficult to standardise, and they depend on the availability of 
      tumour cells. Thus the utilisation of viral vectors genetically modified to 
      express TAA for the ex vivo transduction of DCs is an attractive alternative to 
      achieve a MHC I- and MHC II-restricted presentation of tumoural antigens. To 
      induce protective anti-tumoural immune response an increasing number of modified 
      viral vectors have been used to transduce DCs. Although high transduction 
      efficacies were reported for several viruses, analysis of the interaction of 
      viral vectors with DCs has revealed several viral mechanisms that interfere with 
      main functions of DCs, dampening somewhat the initial optimism in the field of DC 
      transduction. However, promising results with different vectors have been 
      achieved. In this review we summarise available data and discuss advantages and 
      drawbacks of currently available vectors.
FAU - Humrich, J
AU  - Humrich J
AD  - Department of Dermatology, University of Erlangen, Hartmannstrasse 14, 91052 
      Erlangen, Germany.
FAU - Jenne, L
AU  - Jenne L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Curr Top Microbiol Immunol
JT  - Current topics in microbiology and immunology
JID - 0110513
RN  - 0 (Antigens, Viral)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Antigen Presentation/*immunology
MH  - Antigens, Viral/immunology
MH  - Dendritic Cells/*immunology/transplantation/virology
MH  - Dependovirus/genetics
MH  - Genetic Therapy
MH  - Genetic Vectors/immunology/*therapeutic use
MH  - Humans
MH  - *Immunotherapy
MH  - Lentivirus/genetics
MH  - Orthomyxoviridae/genetics
MH  - Poxviridae/genetics
MH  - Viral Vaccines/genetics/*immunology/therapeutic use
RF  - 91
EDAT- 2003/06/12 05:00
MHDA- 2003/07/02 05:00
CRDT- 2003/06/12 05:00
PHST- 2003/06/12 05:00 [pubmed]
PHST- 2003/07/02 05:00 [medline]
PHST- 2003/06/12 05:00 [entrez]
AID - 10.1007/978-3-662-06508-2_11 [doi]
PST - ppublish
SO  - Curr Top Microbiol Immunol. 2003;276:241-59. doi: 10.1007/978-3-662-06508-2_11.